At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... driven by slower growth in the HIV ...

including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Gilead Sciences, Inc. (NASDAQ:GILD ... quarter of commercial and operational execution with robust year-over-year revenue performance across HIV, Oncology, and Liver Disease, including 9% growth in ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price ...